PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (...
November 15 2017 - 1:03AM
YASTEST
REGULATED INFORMATION
GHENT, Belgium,
15 November 2017 - Ablynx NV [Euronext
Brussels and Nasdaq: ABLX] today announced, in accordance with
Article 14 of the Belgian Law of 2 May 2007 regarding the
publication of major shareholdings in issuers whose securities are
admitted to trading on a regulated market (the "Transparency Law"),
that it received a notification of shareholdings from Perceptive
Advisors LLC on 13 November 2017.
Perceptive Advisors LLC notified
Ablynx that it holds 3,400,628 voting securities of Ablynx on 30
October 2017, representing 4.55% of the 74,720,644 outstanding
voting rights of Ablynx, and thereby passively downward crossing
the 5% threshold.
The notification contains the
following information:
-
Reason for the
notification: passive crossing of a threshold
-
Notification by: a parent
undertaking or a controlling person
-
Persons subject to the
notification requirement: Perceptive Advisors LLC - Joseph
Edelman
-
Date on which threshold is
crossed: 30 October 2017
-
Threshold that is crossed:
5%
-
Denominator:
74,720,644
-
Details of the
notification: Perceptive Advisors LLC holds 3,400,628 voting
securities of Ablynx
-
Chain of controlled
undertakings through which the holding is effectively being
held: Joseph Edelman controls Perceptive Advisors in accordance
to article 3,§1, 5° of the Companies Code
-
Additional information:
Perceptive Advisors LLC holds 3,150,628 ordinary shares (traded on
Euronext Brussels) and 250,000 American Depository Shares (traded
on Nasdaq) of Ablynx
More information is provided in the transparency notification. Full
versions of the transparency notifications are available on Ablynx
website, under the section Investors.
The Articles of the Association of
Ablynx NV provide for shareholders notification threshold of 3%, 5%
or a multiple of 5% of the total number of existing voting
rights.
About
Ablynx
Ablynx is a biopharmaceutical
company engaged in the development of Nanobodies, proprietary
therapeutic proteins based on single-domain antibody fragments,
which combine the advantages of conventional antibody drugs with
some of the features of small-molecule drugs. Ablynx is dedicated
to creating new medicines which will make a real difference to
society. Today, the Company has more than 45 proprietary and
partnered programmes in development in various therapeutic areas
including inflammation, haematology, immuno-oncology, oncology and
respiratory disease. The Company has collaborations with multiple
pharmaceutical companies including AbbVie; Boehringer Ingelheim;
Eddingpharm; Merck & Co., Inc., Kenilworth, New Jersey, USA;
Merck KGaA; Novartis; Novo Nordisk; Sanofi and Taisho
Pharmaceuticals. The Company is headquartered in Ghent, Belgium.
More information can be found on www.ablynx.com.
For more
information, please contact
Ablynx:
Dr Edwin Moses
CEO
t: +32 (0)9 262 00 07
m: +32 (0)473 39 50 68
e: edwin.moses@ablynx.com
Lies Vanneste
Director Investor Relations
t: +32 (0)9 262 01 37
m: +32 (0)498 05 35 79
e: lies.vanneste@ablynx.com
Follow us on Twitter @AblynxABLX
Ablynx media
relations:
Consilium Strategic Communications
Mary-Jane Elliott, Philippa Gardner, Sukaina Virji
t: +44 (0)20 3709 5700
e: ablynx@consilium-comms.com
Disclaimer
Certain statements, beliefs and opinions in this press release are
forward-looking, which reflect the Company or, as appropriate, the
Company directors' current expectations and projections about
future events. By their nature, forward-looking statements involve
a number of risks, uncertainties and assumptions that could cause
actual results or events to differ materially from those expressed
or implied by the forward-looking statements. These risks,
uncertainties and assumptions could adversely affect the outcome
and financial effects of the plans and events described herein. A
multitude of factors including, but not limited to, changes in
demand, competition and technology, can cause actual events,
performance or results to differ significantly from any anticipated
development. Forward looking statements contained in this press
release regarding past trends or activities should not be taken as
a representation that such trends or activities will continue in
the future. As a result, the Company expressly disclaims any
obligation or undertaking to release any update or revisions to any
forward-looking statements in this press release as a result of any
change in expectations or any change in events, conditions,
assumptions or circumstances on which these forward-looking
statements are based. Neither the Company nor its advisers or
representatives nor any of its parent or subsidiary undertakings or
any such person's officers or employees guarantees that the
assumptions underlying such forward-looking statements are free
from errors nor does either accept any responsibility for the
future accuracy of the forward-looking statements contained in
this press release or the actual occurrence of the forecasted
developments. You should not place undue reliance on
forward-looking statements, which speak only as of the date of this
press release.
pdf version of the press
release
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Ablynx via Globenewswire
Ablynx NV (NASDAQ:ABLX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ablynx NV (NASDAQ:ABLX)
Historical Stock Chart
From Apr 2023 to Apr 2024